Revolution Medicines said daraxonrasib, its KRAS-targeted drug for metastatic pancreatic cancer, met early goals in a Phase 3 checkpoint and the company ended the study early after survival benefits at an interim analysis. In the RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy, a 60% relative risk reduction at the interim look. Revolution’s results were reported for a registrational setting in patients whose metastatic disease had returned after prior treatment. The FDA has already granted daraxonrasib a national priority voucher, which could compress the approval timeline after a submission. Revolution plans to present additional trial details at an upcoming American Society of Clinical Oncology meeting, and investors focused on whether the strongest benefit was driven by the RAS G12-mutated subgroup.